

Table S1. YM155 concentrations that reduce the viability of neuroblastoma cell lines by 50% (IC₅₀, mean ± S.D., n = 3) as indicated by MTT assay after 120h of incubation.

Cell line	YM155 IC ₅₀ (nM)	Cell line	YM155 IC ₅₀ (nM)
Be(2)-C	24.25 ± 2.59	NLF ^r GEMCI ²⁰	1.84 ± 0.47 (0.1)
CHP-134	2.64 ± 0.50	NLF ^r IRINO ¹⁰⁰⁰	6.93 ± 0.71 (0.3)
GIMEN	33.74 ± 2.26	NLF ^r MEL ³⁰⁰⁰	15.36 ± 3.20 (0.6)
IMR-5	7.18 ± 1.04	NLF ^r OXALI ⁴⁰⁰⁰	33.67 ± 2.67 (1.3)
IMR-5 ^r CARBO ⁵⁰⁰⁰ (1)	8.55 ± 2.01 (1.2) ²	NLF ^r VCR ¹⁰	334.5 ± 21.6 (12.5)
IMR-5 ^r CDDP ¹⁰⁰⁰	19.71 ± 5.70 (2.7)	NLF ^r VINB ¹⁰	38.10 ± 12.02 (1.4)
IMR-5 ^r DOCE ²⁰	21549 ± 638 (3001)	NMB	6.41 ± 1.17
IMR-5 ^r DOX ²⁰	116.3 ± 21.6 (16.2)	SHEP	10.15 ± 0.84
IMR-5 ^r ETO ¹⁰⁰	8.29 ± 3.95 (1.2)	SHEP ^r CDDP ¹⁰⁰⁰	30.83 ± 2.24 (13.7)
IMR-5 ^r GEMCI ²⁰	7.08 ± 1.20 (1.0)	SHEP ^r ETO ¹⁰⁰	20.24 ± 10.16 (2.0)
IMR-5 ^r MEL ¹⁰⁰⁰	11.10 ± 1.57 (1.5)	SHEP ^r VCR ¹⁰	20.95 ± 1.45 (2.1)
IMR-5 ^r OXALI ⁴⁰⁰⁰	10.18 ± 2.69 (1.4)	SH-SY5Y	31.8 ± 6.50
IMR-5 ^r TOPO ²⁰	4.88 ± 1.72 (0.7)	SK-N-AS	3.55 ± 0.21
IMR-5 ^r VCR ¹⁰	472.9 ± 97.4 (65.9)	SK-N-SH	74.94 ± 19.52
IMR-5 ^r VINB ²⁰	1608 ± 212 (224)	UKF-NB-2	4.18 ± 0.27
IMR-5 ^r VINOR ²⁰	4978 ± 147 (693)	UKF-NB-2 ^r CARBO ²⁰⁰⁰	318.2 ± 42.7 (76.1)
IMR-32	1.40 ± 0.35	UKF-NB-2 ^r CDDP ¹⁰⁰⁰	1.15 ± 1.21 (0.3)
IMR-32 ^r CARBO ¹⁰⁰⁰	9.35 ± 0.97	UKF-NB-2 ^r DOCE ¹⁰	1108 ± 179 (265)
IMR-32 ^r DOX ²⁰	35.63 ± 2.23 (5.0)	UKF-NB-2 ^r DOX ²⁰	347.0 ± 55.2 (83.0)
IMR-32 ^r ETO ¹⁰⁰	1.53 ± 0.13 (0.2)	UKF-NB-2 ^r OXALI ⁶⁰⁰	3.25 ± 0.64 (0.8)
IMR-32 ^r GEMCI ²⁰	2.16 ± 0.22 (0.3)	UKF-NB-2 ^r VCR ¹⁰	5940 ± 247 (1421)
IMR-32 ^r OXALI ⁸⁰⁰	0.60 ± 0.02 (0.1)	UKF-NB-3	0.49 ± 0.10
IMR-32 ^r TOPO ^{7.5}	0.45 ± 0.06 (0.1)	UKF-NB-3 ^r CARBO ²⁰⁰⁰	155.4 ± 24.6 (317)
IMR-32 ^r VINOR ⁵	16.43 ± 1.08 (2.3)	UKF-NB-3 ^r CDDP ¹⁰⁰⁰	5.32 ± 1.21 (10.9)
LAN-6	248.1 ± 32.9	UKF-NB-3 ^r DOCE ¹⁰	469.6 ± 113.1 (958)
NB-S-124	76.66 ± 6.51	UKF-NB-3 ^r DOX ²⁰	15,700 ± 1,019 (32041)
NGP	12.48 ± 3.01	UKF-NB-3 ^r ETO ²⁰⁰	7.97 ± 0.13 (16.3)
NGP ^r CARBO ⁵⁰⁰⁰	112.3 ± 5.0 (9.0)	UKF-NB-3 ^r GEMCI ¹⁰	0.40 ± 0.01 (0.8)
NGP ^r CDDP ¹⁰⁰⁰	13.00 ± 0.42 (1.0)	UKF-NB-3 ^r Nutlin ^{10μM}	1.18 ± 0.07 (2.4)
NGP ^r DACARB ¹⁸	20.59 ± 1.84 (1.6)	UKF-NB-3 ^r OXALI ⁴⁰⁰⁰	1.80 ± 0.78 (3.7)
NGP ^r DOCE ²⁰	159.0 ± 19.5 (12.7)	UKF-NB-3 ^r TOPO ²⁰	7.40 ± 0.71 (15.1)
NGP ^r DOX ²⁰	306.9 ± 78.5 (24.6)	UKF-NB-3 ^r VCR ¹⁰	26.59 ± 6.37 (54.3)
NGP ^r ETO ⁴⁰⁰	59.20 ± 11.40 (4.7)	UKF-NB-6	0.65 ± 0.09
NGP ^r GEMCI ²⁰	41.55 ± 6.13 (3.3)	UKF-NB-6 ^r CARBO ²⁰⁰⁰	16.83 ± 1.62 (25.9)
NGP ^r MEL ³⁰⁰⁰	26.10 ± 3.86 (2.1)	UKF-NB-6 ^r CDDP ²⁰⁰⁰	79.93 ± 7.14 (123)
NGP ^r OXALI ⁴⁰⁰⁰	6.93 ± 0.28 (0.6)	UKF-NB-6 ^r DOCE ¹⁰	14.33 ± 4.08 (22.0)
NGP ^r VCR ²⁰	6986 ± 715 (560)	UKF-NB-6 ^r DOX ²⁰	11.80 ± 1.56 (18.2)
NLF	26.78 ± 4.04	UKF-NB-6 ^r ETO ²⁰⁰	3.60 ± 0.01 (5.5)
NLF ^r CARBO ⁵⁰⁰⁰	340.5 ± 34.5 (12.7)	UKF-NB-6 ^r GEMCI ¹⁰	2.10 ± 0.84 (3.2)
NLF ^r CDDP ⁵⁰⁰	12.58 ± 5.39 (0.5)	UKF-NB-6 ^r OXALI ⁴⁰⁰⁰	5.34 ± 0.71 (8.2)
NLF ^r DOCE ²⁰	21.6 ± 5.98 (0.8)	UKF-NB-6 ^r TOPO ²⁰	3.47 ± 0.81 (5.3)
NLF ^r DOX ⁴⁰	34.88 ± 4.33 (1.3)	UKF-NB-6 ^r VCR ¹⁰	49.30 ± 2.24 (75.8)
NLF ^r ETO ¹⁰⁰	7.40 ± 0.54 (0.3)	UKF-NB-6 ^r VINOR ⁴⁰	228.5 ± 41.5 (352)

¹ CARBO, carboplatin; CDDP, cisplatin; DACARB, dacarbazine; DOX, doxorubicin; ETO, etoposide; GEMCI, gemcitabine; IRINO, irinotecan; MEL, melphalan; Nutlin, nutlin-3; OXALI, oxaliplatin; TOPO, topotecan; VCR, vincristine; VINB, vinblastine; VINOR, vinorelbine

² fold difference IC₅₀ resistant sub-line/ IC₅₀ respective parental cell line